Background We compared the efficacy and safety of 1-and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Methods Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Results Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were B0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. Conclusions There was no difference in the efficacy or safety between the 1-and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide.
Introduction
Ever since Huggins and Hodges [1] reported the hormone dependency of prostate cancer in 1941, androgen deprivation therapy (ADT) has been the standard medical therapy. Initially, surgical castration or estrogen therapy was used as ADT. However, with the introduction of luteinizing hormone-releasing hormone (LH-RH) agonists, medical castration has become widely used worldwide.
Two such agonists, goserelin acetate and leuprorelin acetate, are now approved for clinical use in Japan, and 1-and 3-month depots are currently available. Advantages of the 3-month depot include reductions of: (1) hospital visits by one-third, (2) physical and/or psychological burden with the injections, (3) and drug costs. Because of these benefits, use of the 3-month depot from the start of treatment is ideal. However, while reports are available on the efficacy and safety of the 3-month depot administered as the initial treatment in Western patients [2, 3] , there is only one report, based on a very small population, that has evaluated the efficacy and safety in Japanese patients [4] . Because of this minimal substantiation, many Japanese physicians start treatment with the 1-month depot and then switch to the 3-month depot after confirming the efficacy and safety of the 1-month depot. Accordingly, to evaluate this type of protocol, we performed a clinical study to compare the efficacy and safety of the LH-RH agonist goserelin acetate in patients who received the 3-month depot from the start of treatment with those who initially received the 1-month depot for the first 3 months and then switched to the 3-month depot.
Patients and methods
This was a multicenter, randomized controlled study with an open-label, parallel group design and was approved by the institutional review board at the Shinshu University Hospital and at each of the other participating hospitals (see Appendix). All patients provided written informed consent. Between June 1, 2007, and December 31, 2010, 120 patients were recruited from Shinshu University Hospital (Matsumoto, Japan) and hospitals in its neighborhood. The study included patients with International Union Against Cancer (2002) [5] clinical stage T3-4, NX, and MX advanced prostate cancer or T1-2, N0, or M0 prostate cancer for whom other therapies were not selected. Eligible patients needed to have an Eastern Cooperative Oncology Group performance status [6] of 0 or 1, white blood cell count of at least 3000/mm 3 , hemoglobin of more than 10.0 g/dL, platelet count of more than 7.5 9 10 4 /mm 3 , aspartate aminotransferase (AST) of\2.5 9 upper limit of normal (ULN), alanine aminotransferase (ALT) of\2.5 9 ULN, alkaline phosphatase (ALP) of\2.5 9 ULN, and creatinine of\1.5 9 ULN at study entry. Patients with a history of hormonal therapy (surgical and medical castration), chemotherapy, operative therapy, or radiation therapy were excluded. Patients meeting any of the following criteria were withdrawn from the study: (1) disease progression; (2) any adverse event that, in the opinion of the physicians, justified the discontinuation of treatment; (3) toxicity of Grade 4 (http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm); or (4) withdrawal of consent for participation by the patient.
The patients were randomly assigned to the Switch Group (n = 60) or the Direct Group (n = 60). Patients in the Switch Group were initially treated monthly with injections of a 1-month depot of goserelin acetate (Zoladex Ò 3.6 mg depot; AstraZeneca, Osaka, Japan) for 3 months. They were then switched to a 3-month depot (Zoladex LA Ò 10.8 mg depot). In the Direct Group, the 3-month depot of goserelin acetate (Zoladex LA Ò 10.8 mg depot) was administered at the start of the treatment and then again 3 months later. In Japan, to ensure complete androgen blockade, treatment with an LH-RH agonist is often accompanied by treatment with an antiandrogen agent. This combined androgen blockade (CAB) also reduces the possibility of a flare-up associated with the LH-RH agonist alone. Therefore, we supplemented the goserelin acetate with the orally administered antiandrogen agent bicalutamide (Casodex Ò 80 mg; AstraZeneca) once daily during the treatment period.
Clinical data
Patient backgrounds, including clinical stage, Gleason score [7] , and prostate-specific antigen (PSA) level at diagnosis, were collected at the time of registration. Blood samples were taken in the morning before the administration of the LH-RH agonist, as well as at weeks 4, 8, 12, and 24. Total testosterone was measured by radioimmunoassay (Mitsubishi Chemical Medience, Tokyo, Japan). Other laboratory data, including PSA, were measured at each hospital.
Endpoints and statistical analysis
The primary endpoint was the suppression of serum testosterone at weeks 4, 8, 12, and 24. Student's t test was used to compare the testosterone levels between the two groups. Successful castration was defined as achieving a serum testosterone level of B0.50 ng/mL, and the proportion of patients in each group achieving that level of suppression was determined. Secondary endpoints were the mean values of PSA and normalization rates, defined as the proportion of patients with PSA levels \4.0 ng/mL at weeks 4, 8, 12, and 24.
Adverse events were evaluated during the entire treatment period by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, ver. 3.0) (http:// ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm). All Grade 1 or greater adverse events, including laboratory test abnormalities, were summarized. The v 2 test or Fisher's exact test was used to compare the proportions of adverse events between the groups. Incidences of adverse events were summarized for four periods: weeks 0-4, weeks 5-8, weeks 9-12, and weeks 13-24.
All statistical tests were two-sided, and the data were analyzed using SPSS Ò version 18.0 (SPSS, Chicago, IL, USA).
Results
After the randomized distribution into the two study groups, four patients in the Switch Group dropped out by withdrawing consent. Also, 15 patients (9 in the Switch Group and 6 in the Direct Group) were excluded from the analysis because, through error, they received only a small portion of the protocol treatment or some test data were not measured. Thus, 47 patients in the Switch Group and 54 patients in the Direct Group were included in the analysis.
Patient characteristics
The mean age in the Switch Group was 76.3 years, which was slightly, but not significantly, higher than the age (75.0 years) in the Direct Group (Table 1) . Although the Gleason score and performance status were slightly higher in the Direct Group, there were no significant differences between the two groups (P = 0.290 and P = 0.282, respectively). Other factors, including testosterone and PSA levels and clinical stages, were also well balanced between the two groups.
Testosterone suppression
At the initial diagnosis, the testosterone levels in the Switch Group and the Direct Group were 4.98 and 5.07 ng/mL, respectively (P = 0.798, Table 1 ). At week 4, the levels in both groups ( Fig. 1 ) had dropped significantly, to 0.13 ng/mL (P \ 0.001) and 0.17 ng/mL (P \ 0.001) in the Switch Group and the Direct Group, respectively. There was no significant difference between the two groups (P = 0.189).
After week 8, the testosterone levels remained at B0.20 ng/mL in both groups, with no significant difference between them (Fig. 1 ). While most of the patients were maintained at the castration level of B0.50 ng/mL after week 4 (Table 2) , a temporary escape from the castration range occurred in two patients in the Direct Group. In one patient, the testosterone level at baseline was 4.88 ng/mL, and it had decreased to only 1.35 ng/mL 4 weeks after the administration of the goserelin 3-month depot. However, at weeks 8 and 12, the levels were suppressed below the castration range. In the other patient, the testosterone level at baseline was 6.00 ng/mL and the levels were suppressed to 0.30 ng/mL and 0.07 ng/mL at weeks 4 and 8, respectively. However, the level increased to 0.77 ng/mL at week 12, but then decreased again to 0.27 ng/mL at week 24.
Prostate-specific antigen
The mean PSA levels in the Switch and Direct Groups at week 4 had dropped to 8.99 and 8.53 ng/mL, respectively, from the baseline ( Table 3 ). The levels continued to decrease gradually, reaching 1.01 and 0.91 ng/mL, respectively, at week 24. There were no significant differences between the groups in the PSA levels at any Adverse events
There were more adverse events in the period of weeks 0-4 than in any other period. During that time, the occurrence of adverse events in the Switch Group, 53.2 % (25/47), was slightly lower than that in the Direct Group, 57.4 % (31/54), but the difference was not significant (P = 0.671). During the period of weeks 5-8, there were more occurrences of adverse events in the Switch Group, 19.1 % (9/47), compared to the Direct Group, 9.3 % (5/54), but the difference was not significant (P = 0.151). While the cumulative incidence through week 8 was 72.3 % (34/47) in the Switch Group, slightly higher than the 66.7 % (36/54) in the Direct Group, the difference was not significant (P = 0.538). After week 9, the number of adverse events gradually decreased, and the incidences throughout the whole study period were comparable in the two groups, at 88.1 % (37/42) in the Switch Group and 82.4 % (42/51) in the Direct Group (Fig. 2) . On the advice of the attending physicians, three patients in the Direct Group were withdrawn due to adverse events ( Table 4 ). The first patient had an onset of peripheral edema of Grade 1 in the period of week 0-4, but the symptoms disappeared after discontinuation of bicalutamide. In the second patient, AST and ALT increases of Grade 3 occurred at week 8. These values became normalized after 1 month following discontinuation of bicalutamide. In the third patient, AST, ALT, and ALP levels were slightly elevated at week 4 with increases of Grade 1. The discontinuation of bicalutamide resulted in the normalization of these values in the following month. No patient from the Switch Group was withdrawn from the protocol treatment due to any adverse event.
Discussion
While there were no differences in testosterone levels between the two groups in this study, escape from the castration level of 0.5 ng/mL occurred in two patients in the Direct Group. For these two patients, there was no sign of flare-up, and PSA levels decreased over time. There are several other studies that describe cases of testosterone [9] reported an escape rate of 10 % for patients receiving leuprorelin acetate 3-month depot. Of note, some reports indicate that more than 10 % of patients do not reach the castration levels of testosterone with surgical castration (orchidectomy) [10, 11] . These unexpected findings could be the result of individual differences in adrenal androgen concentration [11] . As the escape from the castration level observed in the present study was transient, and PSA was stably maintained at low levels, we believe that the efficacy of the 3-month goserelin acetate depot from the beginning of treatment is comparable to the treatment started with the 1-month depot. Japanese and other studies have shown that there are no differences in adverse events and safety profiles between the 1-and 3-month depots when goserelin acetate is used alone [2] [3] [4] . In the study reported here, the antiandrogen bicalutamide was used in conjunction with the goserelin acetate. We found no difference in the incidence of adverse events between our two groups, and thus we consider that the safety of treatment initiated with the 3-month depot is comparable to that of treatment initiated with the 1-month depot. In this study, three patients in the Direct Group had adverse events leading to treatment discontinuation. One patient had peripheral edema and two had abnormalities in liver enzymes; however, all three patients recovered after bicalutamide was discontinued. Therefore, these adverse events were considered to be associated with bicalutamide. Liver damage and liver failure are known adverse reactions to bicalutamide (http://www.drugs.com/pro/casodex.html), and therefore hepatic function must be monitored regularly when this agent is used. Accordingly, regardless of the formulation of the LH-RH agonist, we consider that patients who are on CAB therapy should be monitored monthly for adverse events, beginning immediately after treatment is initiated. For patients using the 3-month depot, the benefit of reduced frequency of hospital visits will be lost. However, the other advantages, such as alleviated pain with the reduced number of administrations and reduced drug cost, still remain.
In summary, this study has shown that the efficacy and safety of the 3-month depot of goserelin acetate are comparable with that of the 1-month depot.
